nodes	percent_of_prediction	percent_of_DWPC	metapath
Efavirenz—CYP1A2—chronic obstructive pulmonary disease	0.391	1	CbGaD
Efavirenz—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0431	0.1	CbGbCtD
Efavirenz—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0431	0.1	CbGbCtD
Efavirenz—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0359	0.0835	CbGbCtD
Efavirenz—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0359	0.0835	CbGbCtD
Efavirenz—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0338	0.0788	CbGbCtD
Efavirenz—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0328	0.0763	CbGbCtD
Efavirenz—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0328	0.0763	CbGbCtD
Efavirenz—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0292	0.068	CbGbCtD
Efavirenz—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0275	0.0641	CbGbCtD
Efavirenz—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0272	0.0633	CbGbCtD
Efavirenz—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0186	0.0433	CbGbCtD
Efavirenz—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0181	0.0422	CbGbCtD
Efavirenz—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0177	0.0413	CbGbCtD
Efavirenz—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0158	0.0368	CbGbCtD
Efavirenz—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00927	0.0216	CbGbCtD
Efavirenz—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00876	0.0204	CbGbCtD
Efavirenz—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000284	0.00859	CbGpPWpGaD
Efavirenz—CYP1A2—Estrogen Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.000274	0.00829	CbGpPWpGaD
Efavirenz—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000274	0.00829	CbGpPWpGaD
Efavirenz—CYP2C19—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000255	0.00771	CbGpPWpGaD
Efavirenz—CYP2C19—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000249	0.00754	CbGpPWpGaD
Efavirenz—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000247	0.00746	CbGpPWpGaD
Efavirenz—CYP2C19—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00024	0.00725	CbGpPWpGaD
Efavirenz—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000234	0.00709	CbGpPWpGaD
Efavirenz—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000232	0.00702	CbGpPWpGaD
Efavirenz—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000229	0.00694	CbGpPWpGaD
Efavirenz—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000227	0.00688	CbGpPWpGaD
Efavirenz—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000224	0.00679	CbGpPWpGaD
Efavirenz—CYP1A2—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000223	0.00674	CbGpPWpGaD
Efavirenz—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00022	0.00667	CbGpPWpGaD
Efavirenz—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000219	0.00661	CbGpPWpGaD
Efavirenz—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000215	0.0065	CbGpPWpGaD
Efavirenz—CYP1A2—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000211	0.00639	CbGpPWpGaD
Efavirenz—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000206	0.00624	CbGpPWpGaD
Efavirenz—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000205	0.00619	CbGpPWpGaD
Efavirenz—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000198	0.006	CbGpPWpGaD
Efavirenz—CYP2C19—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000198	0.00598	CbGpPWpGaD
Efavirenz—CYP1A2—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000194	0.00588	CbGpPWpGaD
Efavirenz—CYP2B6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000193	0.00583	CbGpPWpGaD
Efavirenz—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000189	0.0057	CbGpPWpGaD
Efavirenz—CYP1A2—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000187	0.00565	CbGpPWpGaD
Efavirenz—CYP2B6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000186	0.00563	CbGpPWpGaD
Efavirenz—CYP2C19—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000185	0.0056	CbGpPWpGaD
Efavirenz—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000183	0.00125	CcSEcCtD
Efavirenz—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000183	0.00125	CcSEcCtD
Efavirenz—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000182	0.00124	CcSEcCtD
Efavirenz—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000182	0.0055	CbGpPWpGaD
Efavirenz—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000182	0.00124	CcSEcCtD
Efavirenz—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000182	0.00124	CcSEcCtD
Efavirenz—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000181	0.00124	CcSEcCtD
Efavirenz—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000181	0.00124	CcSEcCtD
Efavirenz—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000181	0.00124	CcSEcCtD
Efavirenz—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000181	0.00124	CcSEcCtD
Efavirenz—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00018	0.00123	CcSEcCtD
Efavirenz—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00018	0.00123	CcSEcCtD
Efavirenz—Cough—Salbutamol—chronic obstructive pulmonary disease	0.00018	0.00123	CcSEcCtD
Efavirenz—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000179	0.00542	CbGpPWpGaD
Efavirenz—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000178	0.00121	CcSEcCtD
Efavirenz—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.0012	CcSEcCtD
Efavirenz—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.0012	CcSEcCtD
Efavirenz—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.0012	CcSEcCtD
Efavirenz—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000175	0.0012	CcSEcCtD
Efavirenz—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.00119	CcSEcCtD
Efavirenz—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000174	0.00119	CcSEcCtD
Efavirenz—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.00119	CcSEcCtD
Efavirenz—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000174	0.00119	CcSEcCtD
Efavirenz—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000174	0.00119	CcSEcCtD
Efavirenz—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.00119	CcSEcCtD
Efavirenz—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.00118	CcSEcCtD
Efavirenz—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000173	0.00118	CcSEcCtD
Efavirenz—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000173	0.00118	CcSEcCtD
Efavirenz—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000173	0.00118	CcSEcCtD
Efavirenz—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000172	0.00118	CcSEcCtD
Efavirenz—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000172	0.0052	CbGpPWpGaD
Efavirenz—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000171	0.00117	CcSEcCtD
Efavirenz—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000171	0.00117	CcSEcCtD
Efavirenz—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000171	0.00117	CcSEcCtD
Efavirenz—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000171	0.00117	CcSEcCtD
Efavirenz—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.00017	0.00515	CbGpPWpGaD
Efavirenz—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000169	0.00116	CcSEcCtD
Efavirenz—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000169	0.00115	CcSEcCtD
Efavirenz—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000166	0.00113	CcSEcCtD
Efavirenz—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000165	0.00113	CcSEcCtD
Efavirenz—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.00113	CcSEcCtD
Efavirenz—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000165	0.00113	CcSEcCtD
Efavirenz—CYP2C19—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000165	0.00499	CbGpPWpGaD
Efavirenz—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.00113	CcSEcCtD
Efavirenz—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.000165	0.00112	CcSEcCtD
Efavirenz—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.00112	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	0.000163	0.00494	CbGpPWpGaD
Efavirenz—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000163	0.00111	CcSEcCtD
Efavirenz—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000163	0.00493	CbGpPWpGaD
Efavirenz—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000162	0.00111	CcSEcCtD
Efavirenz—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000162	0.00111	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000162	0.00111	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000162	0.00111	CcSEcCtD
Efavirenz—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.0011	CcSEcCtD
Efavirenz—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000161	0.0011	CcSEcCtD
Efavirenz—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.00016	0.00109	CcSEcCtD
Efavirenz—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00016	0.00109	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000159	0.00108	CcSEcCtD
Efavirenz—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000159	0.00108	CcSEcCtD
Efavirenz—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000159	0.00108	CcSEcCtD
Efavirenz—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000158	0.00108	CcSEcCtD
Efavirenz—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000158	0.00108	CcSEcCtD
Efavirenz—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000158	0.00108	CcSEcCtD
Efavirenz—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000157	0.00107	CcSEcCtD
Efavirenz—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000157	0.00107	CcSEcCtD
Efavirenz—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000157	0.00107	CcSEcCtD
Efavirenz—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000156	0.00107	CcSEcCtD
Efavirenz—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000156	0.00107	CcSEcCtD
Efavirenz—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000155	0.00106	CcSEcCtD
Efavirenz—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000155	0.00106	CcSEcCtD
Efavirenz—CYP1A2—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000154	0.00466	CbGpPWpGaD
Efavirenz—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000154	0.00105	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000154	0.00105	CcSEcCtD
Efavirenz—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000153	0.00105	CcSEcCtD
Efavirenz—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000153	0.00105	CcSEcCtD
Efavirenz—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000153	0.00105	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.00105	CcSEcCtD
Efavirenz—CYP2B6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000153	0.00462	CbGpPWpGaD
Efavirenz—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000152	0.00104	CcSEcCtD
Efavirenz—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000152	0.00104	CcSEcCtD
Efavirenz—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000152	0.00104	CcSEcCtD
Efavirenz—Pain—Formoterol—chronic obstructive pulmonary disease	0.000152	0.00104	CcSEcCtD
Efavirenz—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.00104	CcSEcCtD
Efavirenz—Amnesia—Prednisone—chronic obstructive pulmonary disease	0.000152	0.00104	CcSEcCtD
Efavirenz—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000151	0.00103	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00015	0.00103	CcSEcCtD
Efavirenz—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00015	0.00455	CbGpPWpGaD
Efavirenz—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.00015	0.00103	CcSEcCtD
Efavirenz—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.00015	0.00453	CbGpPWpGaD
Efavirenz—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.00015	0.00102	CcSEcCtD
Efavirenz—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000149	0.00102	CcSEcCtD
Efavirenz—Pain—Montelukast—chronic obstructive pulmonary disease	0.000149	0.00102	CcSEcCtD
Efavirenz—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000149	0.00102	CcSEcCtD
Efavirenz—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.00101	CcSEcCtD
Efavirenz—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000148	0.00101	CcSEcCtD
Efavirenz—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000147	0.00101	CcSEcCtD
Efavirenz—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000147	0.00101	CcSEcCtD
Efavirenz—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000147	0.001	CcSEcCtD
Efavirenz—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000147	0.001	CcSEcCtD
Efavirenz—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000146	0.001	CcSEcCtD
Efavirenz—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000146	0.000998	CcSEcCtD
Efavirenz—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000146	0.000996	CcSEcCtD
Efavirenz—CYP2C19—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000146	0.00441	CbGpPWpGaD
Efavirenz—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000145	0.000994	CcSEcCtD
Efavirenz—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000145	0.000994	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000145	0.000991	CcSEcCtD
Efavirenz—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000145	0.000989	CcSEcCtD
Efavirenz—CYP1A2—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000144	0.00436	CbGpPWpGaD
Efavirenz—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000144	0.00436	CbGpPWpGaD
Efavirenz—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000144	0.000981	CcSEcCtD
Efavirenz—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000144	0.000981	CcSEcCtD
Efavirenz—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000142	0.00431	CbGpPWpGaD
Efavirenz—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000142	0.000973	CcSEcCtD
Efavirenz—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000141	0.000966	CcSEcCtD
Efavirenz—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000141	0.000966	CcSEcCtD
Efavirenz—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000141	0.000961	CcSEcCtD
Efavirenz—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000141	0.000961	CcSEcCtD
Efavirenz—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000141	0.000961	CcSEcCtD
Efavirenz—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000141	0.000961	CcSEcCtD
Efavirenz—CYP2C19—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000141	0.00425	CbGpPWpGaD
Efavirenz—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.00014	0.000958	CcSEcCtD
Efavirenz—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00014	0.000958	CcSEcCtD
Efavirenz—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000139	0.00095	CcSEcCtD
Efavirenz—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000139	0.00095	CcSEcCtD
Efavirenz—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000139	0.000949	CcSEcCtD
Efavirenz—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000139	0.000949	CcSEcCtD
Efavirenz—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000138	0.000946	CcSEcCtD
Efavirenz—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000138	0.000946	CcSEcCtD
Efavirenz—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000138	0.000943	CcSEcCtD
Efavirenz—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000138	0.000941	CcSEcCtD
Efavirenz—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000138	0.000941	CcSEcCtD
Efavirenz—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000137	0.000938	CcSEcCtD
Efavirenz—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000137	0.00414	CbGpPWpGaD
Efavirenz—CYP2B6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000135	0.00409	CbGpPWpGaD
Efavirenz—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000135	0.00408	CbGpPWpGaD
Efavirenz—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000922	CcSEcCtD
Efavirenz—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000134	0.00405	CbGpPWpGaD
Efavirenz—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000133	0.000912	CcSEcCtD
Efavirenz—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000133	0.00402	CbGpPWpGaD
Efavirenz—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000133	0.000907	CcSEcCtD
Efavirenz—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000133	0.000907	CcSEcCtD
Efavirenz—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000131	0.000895	CcSEcCtD
Efavirenz—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000131	0.000895	CcSEcCtD
Efavirenz—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000131	0.00396	CbGpPWpGaD
Efavirenz—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000131	0.000895	CcSEcCtD
Efavirenz—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000131	0.000893	CcSEcCtD
Efavirenz—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.00013	0.00393	CbGpPWpGaD
Efavirenz—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.00013	0.000886	CcSEcCtD
Efavirenz—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000129	0.00391	CbGpPWpGaD
Efavirenz—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000128	0.000877	CcSEcCtD
Efavirenz—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000128	0.00388	CbGpPWpGaD
Efavirenz—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000128	0.000872	CcSEcCtD
Efavirenz—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000128	0.000872	CcSEcCtD
Efavirenz—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000126	0.00086	CcSEcCtD
Efavirenz—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000126	0.00086	CcSEcCtD
Efavirenz—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000126	0.000858	CcSEcCtD
Efavirenz—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000125	0.000854	CcSEcCtD
Efavirenz—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000124	0.000847	CcSEcCtD
Efavirenz—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000124	0.000846	CcSEcCtD
Efavirenz—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000123	0.000842	CcSEcCtD
Efavirenz—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000122	0.000832	CcSEcCtD
Efavirenz—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000122	0.000832	CcSEcCtD
Efavirenz—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000121	0.000828	CcSEcCtD
Efavirenz—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000825	CcSEcCtD
Efavirenz—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.00012	0.000823	CcSEcCtD
Efavirenz—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.00012	0.000819	CcSEcCtD
Efavirenz—CYP2C19—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00012	0.00362	CbGpPWpGaD
Efavirenz—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000119	0.000815	CcSEcCtD
Efavirenz—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000119	0.000812	CcSEcCtD
Efavirenz—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000118	0.000807	CcSEcCtD
Efavirenz—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000118	0.000804	CcSEcCtD
Efavirenz—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000118	0.000804	CcSEcCtD
Efavirenz—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000115	0.00349	CbGpPWpGaD
Efavirenz—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000115	0.000787	CcSEcCtD
Efavirenz—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000115	0.000785	CcSEcCtD
Efavirenz—CYP1A2—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000114	0.00343	CbGpPWpGaD
Efavirenz—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000113	0.000773	CcSEcCtD
Efavirenz—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000113	0.000773	CcSEcCtD
Efavirenz—Rash—Formoterol—chronic obstructive pulmonary disease	0.000112	0.000766	CcSEcCtD
Efavirenz—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000112	0.000766	CcSEcCtD
Efavirenz—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000112	0.000766	CcSEcCtD
Efavirenz—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000112	0.000766	CcSEcCtD
Efavirenz—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000111	0.000761	CcSEcCtD
Efavirenz—Headache—Formoterol—chronic obstructive pulmonary disease	0.000111	0.000761	CcSEcCtD
Efavirenz—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000111	0.00076	CcSEcCtD
Efavirenz—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000111	0.000759	CcSEcCtD
Efavirenz—CYP2B6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000111	0.00336	CbGpPWpGaD
Efavirenz—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000759	CcSEcCtD
Efavirenz—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000111	0.000757	CcSEcCtD
Efavirenz—Rash—Montelukast—chronic obstructive pulmonary disease	0.00011	0.000751	CcSEcCtD
Efavirenz—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00011	0.00075	CcSEcCtD
Efavirenz—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.00011	0.000748	CcSEcCtD
Efavirenz—Depression—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000748	CcSEcCtD
Efavirenz—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000109	0.0033	CbGpPWpGaD
Efavirenz—Headache—Montelukast—chronic obstructive pulmonary disease	0.000109	0.000746	CcSEcCtD
Efavirenz—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000108	0.000737	CcSEcCtD
Efavirenz—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000735	CcSEcCtD
Efavirenz—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000107	0.00073	CcSEcCtD
Efavirenz—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000727	CcSEcCtD
Efavirenz—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000106	0.00321	CbGpPWpGaD
Efavirenz—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000725	CcSEcCtD
Efavirenz—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000106	0.00321	CbGpPWpGaD
Efavirenz—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000106	0.000724	CcSEcCtD
Efavirenz—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000723	CcSEcCtD
Efavirenz—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000106	0.000723	CcSEcCtD
Efavirenz—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000106	0.000722	CcSEcCtD
Efavirenz—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000106	0.000722	CcSEcCtD
Efavirenz—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000105	0.00319	CbGpPWpGaD
Efavirenz—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000105	0.000719	CcSEcCtD
Efavirenz—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000104	0.000709	CcSEcCtD
Efavirenz—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000104	0.00313	CbGpPWpGaD
Efavirenz—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000103	0.000707	CcSEcCtD
Efavirenz—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.000699	CcSEcCtD
Efavirenz—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000102	0.00309	CbGpPWpGaD
Efavirenz—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.000696	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	9.98e-05	0.00302	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	9.98e-05	0.00302	CbGpPWpGaD
Efavirenz—CYP1A2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	9.98e-05	0.00302	CbGpPWpGaD
Efavirenz—Nausea—Salbutamol—chronic obstructive pulmonary disease	9.98e-05	0.000682	CcSEcCtD
Efavirenz—Discomfort—Prednisolone—chronic obstructive pulmonary disease	9.93e-05	0.000678	CcSEcCtD
Efavirenz—CYP1A2—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	9.83e-05	0.00297	CbGpPWpGaD
Efavirenz—Hallucination—Prednisone—chronic obstructive pulmonary disease	9.8e-05	0.00067	CcSEcCtD
Efavirenz—CYP2B6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	9.77e-05	0.00296	CbGpPWpGaD
Efavirenz—CYP1A2—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	9.72e-05	0.00294	CbGpPWpGaD
Efavirenz—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	9.68e-05	0.000662	CcSEcCtD
Efavirenz—CYP2B6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	9.66e-05	0.00292	CbGpPWpGaD
Efavirenz—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	9.52e-05	0.00288	CbGpPWpGaD
Efavirenz—Shock—Prednisolone—chronic obstructive pulmonary disease	9.48e-05	0.000648	CcSEcCtD
Efavirenz—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	9.44e-05	0.00286	CbGpPWpGaD
Efavirenz—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	9.4e-05	0.000642	CcSEcCtD
Efavirenz—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	9.4e-05	0.00284	CbGpPWpGaD
Efavirenz—CYP1A2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	9.33e-05	0.00282	CbGpPWpGaD
Efavirenz—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	9.31e-05	0.00282	CbGpPWpGaD
Efavirenz—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	9.31e-05	0.000636	CcSEcCtD
Efavirenz—Eye disorder—Prednisone—chronic obstructive pulmonary disease	9.21e-05	0.000629	CcSEcCtD
Efavirenz—Flushing—Prednisone—chronic obstructive pulmonary disease	9.14e-05	0.000625	CcSEcCtD
Efavirenz—Angiopathy—Prednisone—chronic obstructive pulmonary disease	8.94e-05	0.000611	CcSEcCtD
Efavirenz—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	8.9e-05	0.000608	CcSEcCtD
Efavirenz—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	8.8e-05	0.000601	CcSEcCtD
Efavirenz—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	8.76e-05	0.00265	CbGpPWpGaD
Efavirenz—Insomnia—Prednisolone—chronic obstructive pulmonary disease	8.71e-05	0.000595	CcSEcCtD
Efavirenz—Alopecia—Prednisone—chronic obstructive pulmonary disease	8.71e-05	0.000595	CcSEcCtD
Efavirenz—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	8.65e-05	0.000591	CcSEcCtD
Efavirenz—Erythema—Prednisone—chronic obstructive pulmonary disease	8.58e-05	0.000586	CcSEcCtD
Efavirenz—Malnutrition—Prednisone—chronic obstructive pulmonary disease	8.58e-05	0.000586	CcSEcCtD
Efavirenz—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	8.57e-05	0.00259	CbGpPWpGaD
Efavirenz—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	8.45e-05	0.00256	CbGpPWpGaD
Efavirenz—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	8.39e-05	0.00254	CbGpPWpGaD
Efavirenz—Pain—Prednisolone—chronic obstructive pulmonary disease	8.24e-05	0.000563	CcSEcCtD
Efavirenz—CYP2B6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	8.12e-05	0.00246	CbGpPWpGaD
Efavirenz—Vision blurred—Prednisone—chronic obstructive pulmonary disease	8.08e-05	0.000552	CcSEcCtD
Efavirenz—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	8.07e-05	0.00244	CbGpPWpGaD
Efavirenz—CYP2B6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	8.01e-05	0.00242	CbGpPWpGaD
Efavirenz—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	7.96e-05	0.00241	CbGpPWpGaD
Efavirenz—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	7.96e-05	0.000544	CcSEcCtD
Efavirenz—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	7.94e-05	0.000542	CcSEcCtD
Efavirenz—Anaemia—Prednisone—chronic obstructive pulmonary disease	7.93e-05	0.000542	CcSEcCtD
Efavirenz—Agitation—Prednisone—chronic obstructive pulmonary disease	7.88e-05	0.000539	CcSEcCtD
Efavirenz—Angioedema—Prednisone—chronic obstructive pulmonary disease	7.84e-05	0.000536	CcSEcCtD
Efavirenz—Malaise—Prednisone—chronic obstructive pulmonary disease	7.73e-05	0.000529	CcSEcCtD
Efavirenz—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	7.72e-05	0.00233	CbGpPWpGaD
Efavirenz—Vertigo—Prednisone—chronic obstructive pulmonary disease	7.71e-05	0.000527	CcSEcCtD
Efavirenz—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	7.7e-05	0.00233	CbGpPWpGaD
Efavirenz—Syncope—Prednisone—chronic obstructive pulmonary disease	7.69e-05	0.000526	CcSEcCtD
Efavirenz—Urticaria—Prednisolone—chronic obstructive pulmonary disease	7.65e-05	0.000523	CcSEcCtD
Efavirenz—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	7.65e-05	0.00231	CbGpPWpGaD
Efavirenz—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	7.54e-05	0.000515	CcSEcCtD
Efavirenz—Convulsion—Prednisone—chronic obstructive pulmonary disease	7.43e-05	0.000508	CcSEcCtD
Efavirenz—Hypertension—Prednisone—chronic obstructive pulmonary disease	7.4e-05	0.000506	CcSEcCtD
Efavirenz—CYP2C19—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	7.38e-05	0.00223	CbGpPWpGaD
Efavirenz—Myalgia—Prednisone—chronic obstructive pulmonary disease	7.3e-05	0.000499	CcSEcCtD
Efavirenz—Arthralgia—Prednisone—chronic obstructive pulmonary disease	7.3e-05	0.000499	CcSEcCtD
Efavirenz—CYP2C19—Biological oxidations—GCLC—chronic obstructive pulmonary disease	7.3e-05	0.00221	CbGpPWpGaD
Efavirenz—Anxiety—Prednisone—chronic obstructive pulmonary disease	7.28e-05	0.000497	CcSEcCtD
Efavirenz—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	7.25e-05	0.000496	CcSEcCtD
Efavirenz—Discomfort—Prednisone—chronic obstructive pulmonary disease	7.21e-05	0.000493	CcSEcCtD
Efavirenz—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	7.1e-05	0.000485	CcSEcCtD
Efavirenz—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	6.94e-05	0.0021	CbGpPWpGaD
Efavirenz—Shock—Prednisone—chronic obstructive pulmonary disease	6.89e-05	0.000471	CcSEcCtD
Efavirenz—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	6.86e-05	0.000469	CcSEcCtD
Efavirenz—Tachycardia—Prednisone—chronic obstructive pulmonary disease	6.83e-05	0.000467	CcSEcCtD
Efavirenz—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	6.81e-05	0.00206	CbGpPWpGaD
Efavirenz—Skin disorder—Prednisone—chronic obstructive pulmonary disease	6.8e-05	0.000465	CcSEcCtD
Efavirenz—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.79e-05	0.00205	CbGpPWpGaD
Efavirenz—CYP2B6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	6.77e-05	0.00205	CbGpPWpGaD
Efavirenz—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	6.77e-05	0.000462	CcSEcCtD
Efavirenz—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.73e-05	0.00204	CbGpPWpGaD
Efavirenz—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.71e-05	0.00203	CbGpPWpGaD
Efavirenz—CYP2B6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	6.68e-05	0.00202	CbGpPWpGaD
Efavirenz—Anorexia—Prednisone—chronic obstructive pulmonary disease	6.67e-05	0.000456	CcSEcCtD
Efavirenz—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.65e-05	0.00201	CbGpPWpGaD
Efavirenz—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	6.54e-05	0.00198	CbGpPWpGaD
Efavirenz—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	6.38e-05	0.000436	CcSEcCtD
Efavirenz—Dizziness—Prednisolone—chronic obstructive pulmonary disease	6.37e-05	0.000435	CcSEcCtD
Efavirenz—Insomnia—Prednisone—chronic obstructive pulmonary disease	6.33e-05	0.000433	CcSEcCtD
Efavirenz—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	6.28e-05	0.000429	CcSEcCtD
Efavirenz—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	6.26e-05	0.00189	CbGpPWpGaD
Efavirenz—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	6.22e-05	0.00188	CbGpPWpGaD
Efavirenz—CYP2B6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	6.22e-05	0.00188	CbGpPWpGaD
Efavirenz—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	6.16e-05	0.000421	CcSEcCtD
Efavirenz—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	6.14e-05	0.00186	CbGpPWpGaD
Efavirenz—CYP2B6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	6.14e-05	0.00186	CbGpPWpGaD
Efavirenz—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.13e-05	0.00186	CbGpPWpGaD
Efavirenz—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	6.08e-05	0.000416	CcSEcCtD
Efavirenz—Rash—Prednisolone—chronic obstructive pulmonary disease	6.07e-05	0.000415	CcSEcCtD
Efavirenz—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	6.07e-05	0.000415	CcSEcCtD
Efavirenz—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.05e-05	0.00183	CbGpPWpGaD
Efavirenz—Fatigue—Prednisone—chronic obstructive pulmonary disease	6.03e-05	0.000412	CcSEcCtD
Efavirenz—Headache—Prednisolone—chronic obstructive pulmonary disease	6.03e-05	0.000412	CcSEcCtD
Efavirenz—Constipation—Prednisone—chronic obstructive pulmonary disease	5.99e-05	0.000409	CcSEcCtD
Efavirenz—CYP2B6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.9e-05	0.00178	CbGpPWpGaD
Efavirenz—CYP2B6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	5.82e-05	0.00176	CbGpPWpGaD
Efavirenz—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	5.77e-05	0.000394	CcSEcCtD
Efavirenz—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	5.75e-05	0.00174	CbGpPWpGaD
Efavirenz—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	5.72e-05	0.000391	CcSEcCtD
Efavirenz—Nausea—Prednisolone—chronic obstructive pulmonary disease	5.72e-05	0.000391	CcSEcCtD
Efavirenz—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5.69e-05	0.00172	CbGpPWpGaD
Efavirenz—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	5.64e-05	0.00171	CbGpPWpGaD
Efavirenz—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	5.59e-05	0.00169	CbGpPWpGaD
Efavirenz—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.56e-05	0.00168	CbGpPWpGaD
Efavirenz—Urticaria—Prednisone—chronic obstructive pulmonary disease	5.56e-05	0.00038	CcSEcCtD
Efavirenz—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	5.53e-05	0.000378	CcSEcCtD
Efavirenz—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	5.53e-05	0.000378	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	5.52e-05	0.00167	CbGpPWpGaD
Efavirenz—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.52e-05	0.00167	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	5.19e-05	0.00157	CbGpPWpGaD
Efavirenz—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	5.16e-05	0.000352	CcSEcCtD
Efavirenz—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.12e-05	0.00155	CbGpPWpGaD
Efavirenz—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.05e-05	0.00153	CbGpPWpGaD
Efavirenz—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	5.05e-05	0.00153	CbGpPWpGaD
Efavirenz—Asthenia—Prednisone—chronic obstructive pulmonary disease	5.02e-05	0.000343	CcSEcCtD
Efavirenz—Pruritus—Prednisone—chronic obstructive pulmonary disease	4.95e-05	0.000338	CcSEcCtD
Efavirenz—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	4.79e-05	0.000327	CcSEcCtD
Efavirenz—CYP2B6—Metabolism—APIP—chronic obstructive pulmonary disease	4.75e-05	0.00144	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	4.73e-05	0.00143	CbGpPWpGaD
Efavirenz—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.71e-05	0.00142	CbGpPWpGaD
Efavirenz—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.7e-05	0.00142	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	4.67e-05	0.00141	CbGpPWpGaD
Efavirenz—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.67e-05	0.00141	CbGpPWpGaD
Efavirenz—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.64e-05	0.0014	CbGpPWpGaD
Efavirenz—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.64e-05	0.0014	CbGpPWpGaD
Efavirenz—Dizziness—Prednisone—chronic obstructive pulmonary disease	4.63e-05	0.000316	CcSEcCtD
Efavirenz—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.6e-05	0.00139	CbGpPWpGaD
Efavirenz—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.46e-05	0.00135	CbGpPWpGaD
Efavirenz—Vomiting—Prednisone—chronic obstructive pulmonary disease	4.45e-05	0.000304	CcSEcCtD
Efavirenz—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.44e-05	0.00134	CbGpPWpGaD
Efavirenz—Rash—Prednisone—chronic obstructive pulmonary disease	4.41e-05	0.000302	CcSEcCtD
Efavirenz—Dermatitis—Prednisone—chronic obstructive pulmonary disease	4.41e-05	0.000301	CcSEcCtD
Efavirenz—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.4e-05	0.00133	CbGpPWpGaD
Efavirenz—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.39e-05	0.00133	CbGpPWpGaD
Efavirenz—Headache—Prednisone—chronic obstructive pulmonary disease	4.38e-05	0.0003	CcSEcCtD
Efavirenz—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.32e-05	0.00131	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	4.29e-05	0.0013	CbGpPWpGaD
Efavirenz—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.29e-05	0.0013	CbGpPWpGaD
Efavirenz—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.27e-05	0.00129	CbGpPWpGaD
Efavirenz—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.23e-05	0.00128	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	4.21e-05	0.00127	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	4.21e-05	0.00127	CbGpPWpGaD
Efavirenz—Nausea—Prednisone—chronic obstructive pulmonary disease	4.16e-05	0.000284	CcSEcCtD
Efavirenz—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.1e-05	0.00124	CbGpPWpGaD
Efavirenz—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.06e-05	0.00123	CbGpPWpGaD
Efavirenz—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.04e-05	0.00122	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	4.04e-05	0.00122	CbGpPWpGaD
Efavirenz—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.01e-05	0.00121	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	4e-05	0.00121	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	4e-05	0.00121	CbGpPWpGaD
Efavirenz—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.99e-05	0.00121	CbGpPWpGaD
Efavirenz—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.93e-05	0.00119	CbGpPWpGaD
Efavirenz—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.69e-05	0.00112	CbGpPWpGaD
Efavirenz—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.66e-05	0.00111	CbGpPWpGaD
Efavirenz—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.64e-05	0.0011	CbGpPWpGaD
Efavirenz—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.61e-05	0.00109	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	3.59e-05	0.00108	CbGpPWpGaD
Efavirenz—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.47e-05	0.00105	CbGpPWpGaD
Efavirenz—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.43e-05	0.00104	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	3.3e-05	0.000998	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	3.27e-05	0.000989	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.14e-05	0.000951	CbGpPWpGaD
Efavirenz—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.08e-05	0.000931	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—GC—chronic obstructive pulmonary disease	3.06e-05	0.000925	CbGpPWpGaD
Efavirenz—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.03e-05	0.000918	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.84e-05	0.00086	CbGpPWpGaD
Efavirenz—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.83e-05	0.000855	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	2.79e-05	0.000845	CbGpPWpGaD
Efavirenz—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.79e-05	0.000844	CbGpPWpGaD
Efavirenz—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.68e-05	0.000811	CbGpPWpGaD
Efavirenz—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.64e-05	0.0008	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.56e-05	0.000773	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.38e-05	0.000719	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.36e-05	0.000713	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.33e-05	0.000705	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	2.31e-05	0.000699	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.18e-05	0.000661	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.17e-05	0.000655	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.16e-05	0.000652	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.15e-05	0.00065	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.15e-05	0.00065	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	2.13e-05	0.000643	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	2.11e-05	0.000637	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.99e-05	0.000603	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.98e-05	0.000598	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.96e-05	0.000593	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.85e-05	0.00056	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.8e-05	0.000545	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.71e-05	0.000518	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.67e-05	0.000506	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.67e-05	0.000505	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.65e-05	0.0005	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.56e-05	0.000472	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.51e-05	0.000456	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.43e-05	0.000432	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.39e-05	0.00042	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.39e-05	0.00042	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.33e-05	0.000403	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.29e-05	0.000391	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.26e-05	0.000382	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	1.25e-05	0.000377	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.16e-05	0.000352	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.16e-05	0.000351	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.16e-05	0.00035	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.15e-05	0.000348	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.15e-05	0.000347	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.14e-05	0.000345	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	1.14e-05	0.000344	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.14e-05	0.000344	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.06e-05	0.000322	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.06e-05	0.000321	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.05e-05	0.000317	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.05e-05	0.000317	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.04e-05	0.000314	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.01e-05	0.000305	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.84e-06	0.000298	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	9.72e-06	0.000294	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.65e-06	0.000292	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.57e-06	0.000289	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	9.07e-06	0.000274	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	8.87e-06	0.000268	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.75e-06	0.000265	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.63e-06	0.000261	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.05e-06	0.000243	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.04e-06	0.000243	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.98e-06	0.000241	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.94e-06	0.00024	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.87e-06	0.000238	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.62e-06	0.000231	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.59e-06	0.00023	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	7.5e-06	0.000227	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.4e-06	0.000224	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.33e-06	0.000222	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.01e-06	0.000212	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.95e-06	0.00021	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—ALB—chronic obstructive pulmonary disease	6.86e-06	0.000207	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	6.85e-06	0.000207	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.82e-06	0.000206	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.72e-06	0.000203	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—NOS3—chronic obstructive pulmonary disease	6.56e-06	0.000198	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.31e-06	0.000191	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.27e-06	0.00019	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.94e-06	0.00018	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.26e-06	0.000159	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.19e-06	0.000157	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	5.18e-06	0.000157	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	4.96e-06	0.00015	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.84e-06	0.000146	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	4.77e-06	0.000144	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	4.72e-06	0.000143	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.58e-06	0.000139	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	4.56e-06	0.000138	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	4.52e-06	0.000137	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	4.04e-06	0.000122	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	3.86e-06	0.000117	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.12e-06	9.43e-05	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.98e-06	9.02e-05	CbGpPWpGaD
